Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
AVBP ArriVent BioPharma Inc.
- Stocks
- Healthcare
- NASDAQ: AVBP
Price (delayed)
$23.06
Market cap
$788.94M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.77
Enterprise value
$739.21M
We are a clinical-stage biopharmaceutical company dedicated to the identification, development and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. We seek to utilize
Highlights
AVBP's debt has dropped by 52% year-on-year and by 22% since the previous quarter
The EPS has soared by 85% YoY but it has contracted by 47% from the previous quarter
ArriVent BioPharma's quick ratio has shrunk by 57% YoY but it has increased by 7% QoQ
The net income has dropped by 71% year-on-year and by 58% since the previous quarter
The equity has contracted by 36% YoY and by 21% from the previous quarter
Key stats
What are the main financial stats of AVBP
Market
Valuations
Earnings
Shares outstanding
34.21M
Market cap
$788.94M
Enterprise value
$739.21M
Price to earnings (P/E)
N/A
Price to book (P/B)
3.87
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$140.41M
Net income
-$127.46M
EBIT
-$127.46M
EBITDA
-$127.46M
Free cash flow
-$119.59M
Per share
Balance sheet
Liquidity
EPS
-$3.77
EPS diluted
-$3.77
Free cash flow per share
-$3.53
Book value per share
$5.95
Revenue per share
$0
TBVPS
$6.36
Total assets
$215.5M
Total liabilities
$12.95M
Debt
$138,000
Equity
$202.54M
Working capital
$172.83M
Debt to equity
0
Current ratio
14.34
Quick ratio
13.59
Net debt/EBITDA
0.39
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-46.7%
Return on equity
-49.3%
Return on invested capital
-154.7%
Return on capital employed
-62.9%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
AVBP stock price
How has the ArriVent BioPharma stock price performed over time
Intraday
-0.22%
1 week
-7.35%
1 month
13.04%
1 year
31.92%
YTD
-13.44%
QTD
24.72%
Financial performance
How have ArriVent BioPharma's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$140.41M
Net income
-$127.46M
Gross margin
N/A
Net margin
N/A
The net income has dropped by 71% year-on-year and by 58% since the previous quarter
ArriVent BioPharma's operating income has plunged by 69% YoY and by 49% from the previous quarter
Price vs fundamentals
How does AVBP's price correlate with its fundamentals
Growth
What is ArriVent BioPharma's growth rate over time
Valuation
What is ArriVent BioPharma stock price valuation
P/E
N/A
P/B
3.87
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has soared by 85% YoY but it has contracted by 47% from the previous quarter
The equity has contracted by 36% YoY and by 21% from the previous quarter
AVBP's P/B is 34% above its last 4 quarters average of 2.9
Efficiency
How efficient is ArriVent BioPharma business performance
ArriVent BioPharma's ROE has plunged by 110% YoY and by 76% from the previous quarter
ArriVent BioPharma's ROA has plunged by 106% YoY and by 75% from the previous quarter
ArriVent BioPharma's ROIC has soared by 98% YoY and by 15% from the previous quarter
Dividends
What is AVBP's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for AVBP.
Financial health
How did ArriVent BioPharma financials performed over time
ArriVent BioPharma's quick ratio has shrunk by 57% YoY but it has increased by 7% QoQ
ArriVent BioPharma's current ratio has shrunk by 56% YoY but it has increased by 9% QoQ
AVBP's debt is 100% smaller than its equity
AVBP's debt has dropped by 52% year-on-year and by 22% since the previous quarter
The equity has contracted by 36% YoY and by 21% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.